Medtronic PLC vs ProShares Ultra Semiconductors — how do they compare? Medtronic PLC trades at $87.69 (market cap $109.38B), while ProShares Ultra Semiconductors trades at $99.11 (market cap $3.15B). The key difference: Medtronic PLC is far larger — about 34.7× ProShares Ultra Semiconductors's market cap, and Medtronic PLC pays a 3.37% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and ProShares Ultra Semiconductors for 29 Days on average.
| MDT | USD | |
|---|---|---|
Market Cap | $109.38B | $3.15B |
Volume | 55,890,185 | 333,862 |
Sector | Health | Leveraged / Inverse |
52-Week High | $105.35 | $113.53 |
52-Week Low | $73.75 | $43.19 |
Typical Hold Time | 63 Days | 29 Days |
Enterprise Value | $128.71B | — |
Dividend Yield | 3.37% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength, though RSI levels suggest potential overbought conditions. Recent corporate action includes a $0.13 dividend scheduled for September 2026. Support levels are established at $100-$102, with resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investment opportunity lies in the bullish technical setup and dividend yield, while risks include potential overbought conditions and lack of current financial metrics. Investors should await updated financial reports for fundamental validation of the current price level.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →